1.Laruelle M: Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20:423–451
2.Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N: Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386:830–833
3.Self DW, Barnhart WJ, Lehman DA, Nestler EJ: Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 1996; 271:1586–1589
4.Khroyan TV, Barrett-Larimore RL, Rowlett JK, Spealman RD: Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J Pharmacol Exp Ther 2000; 294:680–687
5.Shaham Y, Shalev U, Lu L, De Wit H, Stewart J: The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 2003; 168(1–2):3–20
6.Foltin RW, Ward AS, Collins ED, Haney M, Hart CL, Fischman MW: The effects of venlafaxine on the subjective, reinforcing, and cardiovascular effects of cocaine in opioid-dependent and non-opioid-dependent humans. Exp Clin Psychopharmacol 2003; 11:123–130
7.Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y, Perez A, Frankle WG, Cooper T, Kleber HD, Fischman MW, Laruelle M: Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology 2004; 29:1190–1202
8.Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Simpson N, Ngo K, Van Heertum R, Laruelle M: Imaging human mesolimbic dopamine transmission with PET, I: accuracy and precision of D2 parameter measurements in the ventral striatum. J Cereb Blood Flow Metab 2001; 21:1034–1057
9.Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB: Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharmaceutical Sci 1994; 83:1014–1019
10.Reimer ML, Mamer OA, Zavitsanos AP, Siddiqui AW, Dadgar D: Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol Mass Spectrom 1993; 22:235–242
11.Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography, part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23:285–300
12.Slifstein M, Laruelle M: Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 2001; 28:595–608
13.Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography, I: accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21:1034–1057
14.Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frakowiak RSJ: Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 2:189–210
15.Evans SM, Haney M, Foltin RW: The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology (Berl) 2002; 159:397–406
16.Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB: SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36:1182–1190
17.Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain: Three-Dimensional Proportional System. New York, Thieme Medical, 1988
18.Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP: Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993; 14:169–177
19.Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA: Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49:81–96
20.Kalivas PW, Duffy P: Time course of extracellular dopamine and behavioral sensitization to cocaine, I: dopamine axon terminals. J Neurosci 1993; 13:276–284
21.Pettit HO, Pan HT, Parsons LH, Justice JBJ: Extracellular concentration of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem 1990; 55:798–804
22.Bradberry CW: Acute and chronic dopamine dynamics in a nonhuman primate model of recreational cocaine use. J Neurosci 2000; 20:7109–7115
23.Beitner-Johnson D, Guitart X, Nestler EJ: Neurofilament proteins and the mesolimbic dopamine system: common regulation by chronic morphine and chronic cocaine in the rat ventral tegmental area. J Neurosci 1992; 12:2165–2176
24.Robertson MW, Leslie CA, Bennett JP Jr: Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. Brain Res 1991; 538:337–339
25.Rossetti ZL, Hmaidan Y, Gessa GL: Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 1992; 221(2–3):227–234
26.Mateo Y, Lack CM, Morgan D, Roberts DC, Jones SR: Reduced dopamine terminal function and insensitivity to cocaine following cocaine binge self-administration and deprivation. Neuropsychopharmacology 2005; 30:1455–1463
27.Little KY, Zhang L, Desmond T, Frey KA, Dalack GW, Cassin BJ: Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry 1999; 156:238–245
28.Little KY, Krolewski DM, Zhang L, Cassin BJ: Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 2003; 160:47–55
29.Wu JC, Bell K, Najafi A, Widmark C, Keator D, Tang C, Klein E, Bunney BG, Fallon J, Bunney WE: Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 1997; 17:402–409
30.Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW: Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997; 25:1–14
31.Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, deBartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94:2569–2574
32.Wise RA: Neurobiology of addiction. Curr Opin Neurobiol 1996; 6:243–251
33.Hassani OK, Cromwell HC, Schultz W: Influence of expectation of different rewards on behavior-related neuronal activity in the striatum. J Neurophysiol 2001; 85:2477–2489
34.Berridge KC, Robinson TE: What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998; 28:309–369
35.Salamone JD, Correa M, Mingote S, Weber SM: Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther 2003; 305:1–8
36.Bindra D: A motivational view of learning, performance, and behavior modification. Psychol Rev 1974; 81:199–213